Found: 239
Select item for more details and to access through your institution.
Heterogeneous Profile of ROR1 Protein Expression across Tumor Types.
- Published in:
- Cancers, 2024, v. 16, n. 10, p. 1874, doi. 10.3390/cancers16101874
- By:
- Publication type:
- Article
KRAS Allelic Variants in Biliary Tract Cancers.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 1, p. e249840, doi. 10.1001/jamanetworkopen.2024.9840
- By:
- Publication type:
- Article
Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2024, v. 31, n. 4, p. 2244, doi. 10.1245/s10434-023-14835-z
- By:
- Publication type:
- Article
ASO Visual Abstract: Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
ASO Visual Abstract: Defining the Biology of Estrogen Receptor-Low Positive Breast Cancer.
- Published in:
- 2024
- By:
- Publication type:
- Abstract
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
- Published in:
- Oncologist, 2024, v. 29, n. 4, p. e514, doi. 10.1093/oncolo/oyad338
- By:
- Publication type:
- Article
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00563-4
- By:
- Publication type:
- Article
Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2024, v. 31, n. 2, p. 974, doi. 10.1245/s10434-023-14541-w
- By:
- Publication type:
- Article
Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 3, p. 400, doi. 10.1002/cncr.35063
- By:
- Publication type:
- Article
Phase I study of sapanisertib (CB‐228/TAK‐228/MLN0128) in combination with ziv‐aflibercept in patients with advanced solid tumors.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 3, p. 1, doi. 10.1002/cam4.6877
- By:
- Publication type:
- Article
Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing.
- Published in:
- Journal of Immunotherapy & Precision Oncology, 2024, v. 7, n. 1, p. 7, doi. 10.36401/JIPO-23-2
- By:
- Publication type:
- Article
To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2023, v. 30, n. 13, p. 8327, doi. 10.1245/s10434-023-14245-1
- By:
- Publication type:
- Article
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-46586-y
- By:
- Publication type:
- Article
Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 17, p. 2685, doi. 10.1002/cncr.34820
- By:
- Publication type:
- Article
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan.
- Published in:
- NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00573-8
- By:
- Publication type:
- Article
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 107, doi. 10.1007/s00280-023-04545-4
- By:
- Publication type:
- Article
A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma.
- Published in:
- Cancers, 2023, v. 15, n. 15, p. 3806, doi. 10.3390/cancers15153806
- By:
- Publication type:
- Article
Actionability classification of variants of unknown significance correlates with functional effect.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00420-w
- By:
- Publication type:
- Article
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00369-w
- By:
- Publication type:
- Article
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2023, v. 30, n. 4, p. 2111, doi. 10.1245/s10434-022-12972-5
- By:
- Publication type:
- Article
ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy – Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Positive Clinical Stage 2–3 Breast Cancer
- Published in:
- 2023
- By:
- Publication type:
- Abstract
Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures.
- Published in:
- Oncologist, 2023, v. 28, n. 4, p. 368, doi. 10.1093/oncolo/oyac204
- By:
- Publication type:
- Article
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-022-00341-0
- By:
- Publication type:
- Article
Antibody-drug conjugates in lung cancer: dawn of a new era?
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-022-00338-9
- By:
- Publication type:
- Article
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers.
- Published in:
- NPJ Breast Cancer, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41523-022-00492-0
- By:
- Publication type:
- Article
Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials.
- Published in:
- Cancers, 2022, v. 14, n. 15, p. 3695, doi. 10.3390/cancers14153695
- By:
- Publication type:
- Article
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-16933-6
- By:
- Publication type:
- Article
Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-12669-5
- By:
- Publication type:
- Article
Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 5, p. e2213070, doi. 10.1001/jamanetworkopen.2022.13070
- By:
- Publication type:
- Article
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 2, p. 290, doi. 10.1007/s10637-021-01188-1
- By:
- Publication type:
- Article
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 3, p. 509, doi. 10.1002/cncr.33968
- By:
- Publication type:
- Article
Artificial intelligence in clinical and translational science: Successes, challenges and opportunities.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 2, p. 309, doi. 10.1111/cts.13175
- By:
- Publication type:
- Article
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 124, doi. 10.1007/s10637-021-01184-5
- By:
- Publication type:
- Article
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-05193-z
- By:
- Publication type:
- Article
Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 2, p. 340, doi. 10.1002/cam4.4446
- By:
- Publication type:
- Article
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition.
- Published in:
- NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00240-w
- By:
- Publication type:
- Article
Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2021, v. 28, n. 10, p. 5477, doi. 10.1245/s10434-021-10444-w
- By:
- Publication type:
- Article
RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient.
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 4950, doi. 10.3390/cancers13194950
- By:
- Publication type:
- Article
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study.
- Published in:
- Investigational New Drugs, 2021, v. 39, n. 5, p. 1357, doi. 10.1007/s10637-021-01119-0
- By:
- Publication type:
- Article
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer.
- Published in:
- Targeted Oncology, 2021, v. 16, n. 5, p. 569, doi. 10.1007/s11523-021-00835-0
- By:
- Publication type:
- Article
Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. 558, doi. 10.1002/onco.13682
- By:
- Publication type:
- Article
Patient‐Reported Out‐of‐Pocket Costs and Financial Toxicity During Early‐Phase Oncology Clinical Trials.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. 588, doi. 10.1002/onco.13767
- By:
- Publication type:
- Article
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.
- Published in:
- OncoTargets & Therapy, 2021, v. 14, p. 3037, doi. 10.2147/OTT.S291801
- By:
- Publication type:
- Article
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
- Published in:
- NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-021-00251-7
- By:
- Publication type:
- Article
Associations between the gut microbiome and fatigue in cancer patients.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-84783-9
- By:
- Publication type:
- Article